Kropp & själ
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
John Geigert
Inbunden
3829:-
Uppskattad leveranstid 10-16 arbetsdagar
Fri frakt för medlemmar vid köp för minst 249:-
Andra format:
- Inbunden 2669:-
- Inbunden 2449:-
- Inbunden 2999:-
- Pocket/Paperback 3069:-
- Pocket/Paperback 2759:-
- Pocket/Paperback 2179:-
- Visa fler Visa färre
This book highlights the challenges facing quality assurance/quality control (QA/QC) in today's biopharmaceutical environment and presents the strategic importance and value generated by QA/QC for their involvement in control of manufacturing. It will put into perspective the need for a graded approach to QA/QC from early clinical trials through market approval. Since the first edition published in 2004, there have been more than 50 new regulatory guidances released by the Food and Drug Administration (FDA), European Medicines Agency (EMA) and ICH that affect the CMC regulatory compliance of biopharmaceuticals; also the application of biosimilars has been developed in Europe and is under development in the USA. The revised update will be broadened to include not only biopharmaceuticals (biotech drugs) but also other biologics (vaccines, cell therapy, plasma-derived proteins, etc.)
- Illustratör: 60 schwarz-weiße Tabellen 8 schwarz-weiße und 15 farbige Abbildungen
- Format: Inbunden
- ISBN: 9781461469155
- Språk: Engelska
- Antal sidor: 338
- Utgivningsdatum: 2013-05-07
- Förlag: Springer-Verlag New York Inc.